FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
The Veterinary record2005; 156(12); 367-371; doi: 10.1136/vr.156.12.367

Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom.

Abstract: Fifteen influenza-naive Welsh mountain ponies were randomly assigned to three groups of five. A single dose of a recombinant ALVAC vaccine was administered intramuscularly to five of the ponies, two doses, administered five weeks apart, were administered to five, and the other five served as unvaccinated, challenge controls. Two weeks after the completion of the vaccination programme, the ponies were all challenged by exposure to an aerosol of influenza virus A/eq/Newmarket/5/03. Their clinical signs were scored daily for 14 days according to a standardised scoring protocol, and nasal swabs were taken daily for 10 days to monitor the excretion of virus. The challenge produced severe clinical signs of influenza (fever, coughing, nasal discharge and dyspnoea) in all five control ponies, but the vaccinated ponies developed only mild disease, consisting of a serous nasal discharge lasting for only one day. The excretion of virus was almost completely suppressed in the vaccinated ponies, but the control ponies shed the virus for up to seven days after the challenge.
Get Full Text
Publication Date: 2005-04-09 PubMed ID: 15816180DOI: 10.1136/vr.156.12.367Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses studying the effectiveness of a new vaccine against a notorious outbreak of equine influenza in the United Kingdom in 2003. A group of ponies were vaccinated and then intentionally exposed to the virus, the purpose being to observe the severity of flu signs and monitor the virus excretion.

Study Design and Procedure

To understand the efficacy of the recombinant ALVAC vaccine against the equine influenza virus, researchers involved fifteen Welsh mountain ponies in their study.

  • These ponies, previously unexposed to the influenza, were split randomly into groups of five.
  • A single dose of the vaccine was intramuscularly administered to the first group. The second group received two doses given five weeks apart. The last group did not receive a vaccination and served as the controls for challenge.

Exposing the Ponies to Virus

Two weeks post completion of the vaccination schedule, the ponies were intentionally exposed to the influenza virus A/eq/Newmarket/5/03 via aerosol. Over the course of two weeks:

  • The ponies’ clinical signs were observed and scored based on a standardized protocol.
  • Their nasal swabs were collected for ten days to monitor virus excretion.

Observations and Findings

The exposure led to severe influenza symptoms (including fever, nasal discharge, coughing, and breathing difficulties) in the non-vaccinated control group while the vaccinated ponies only developed mild illnesses. Key observations included:

  • The vaccinated ponies mainly experienced a serous nasal discharge that lasted only one day.
  • The unvaccinated group, conversely, showcased severe influenza symptoms.
  • In the vaccinated ponies, virus excretion was almost completely halted following vaccination.
  • The control group, however, continued to shed the virus for approximately seven days post-challenge.

The results indicate a successful response to the vaccine, demonstrating its potential effectiveness against equine influenza, especially the strain that caused the 2003 UK outbreak.

Cite This Article

APA
Edlund Toulemonde C, Daly J, Sindle T, Guigal PM, Audonnet JC, Minke JM. (2005). Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec, 156(12), 367-371. https://doi.org/10.1136/vr.156.12.367

Publication

The Veterinary record
ISSN: 0042-4900
NlmUniqueID: 0031164
Country: England
Language: English
Volume: 156
Issue: 12
Pages: 367-371

Researcher Affiliations

Edlund Toulemonde, C
  • Merial SAS, 254 rue Marcel Merieux, 69007, Lyon, France.
Daly, J
    Sindle, T
      Guigal, P M
        Audonnet, J C
          Minke, J M

            MeSH Terms

            • Animals
            • Antibodies, Viral / blood
            • Body Temperature
            • Disease Outbreaks / veterinary
            • Horse Diseases / prevention & control
            • Horses
            • Immunization Schedule
            • Influenza A Virus, H3N8 Subtype
            • Influenza A virus / immunology
            • Influenza Vaccines / administration & dosage
            • Male
            • Orthomyxoviridae Infections / prevention & control
            • Orthomyxoviridae Infections / veterinary
            • United Kingdom
            • Vaccines, Synthetic / administration & dosage

            Citations

            This article has been cited 18 times.
            1. Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front Vet Sci 2021;8:654289.
              doi: 10.3389/fvets.2021.654289pubmed: 33937377google scholar: lookup
            2. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
              doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
            3. de Vries RD, Rimmelzwaan GF. Viral vector-based influenza vaccines. Hum Vaccin Immunother 2016 Nov;12(11):2881-2901.
              doi: 10.1080/21645515.2016.1210729pubmed: 27455345google scholar: lookup
            4. Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary. Pathogens 2016 Jun 10;5(2).
              doi: 10.3390/pathogens5020042pubmed: 27294963google scholar: lookup
            5. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
              doi: 10.3390/vaccines2040797pubmed: 26344892google scholar: lookup
            6. Ozawa M, Kawaoka Y. Cross talk between animal and human influenza viruses. Annu Rev Anim Biosci 2013 Jan;1:21-42.
              doi: 10.1146/annurev-animal-031412-103733pubmed: 25387011google scholar: lookup
            7. Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, Muranaka M, Ueno T, Kinoshita Y, Niwa H, Hidari KI, Suzuki T. No evidence of horizontal infection in horses kept in close contact with dogs experimentally infected with canine influenza A virus (H3N8). Acta Vet Scand 2012 Apr 16;54(1):25.
              doi: 10.1186/1751-0147-54-25pubmed: 22506984google scholar: lookup
            8. Ault A, Zajac AM, Kong WP, Gorres JP, Royals M, Wei CJ, Bao S, Yang ZY, Reedy SE, Sturgill TL, Page AE, Donofrio-Newman J, Adams AA, Balasuriya UB, Horohov DW, Chambers TM, Nabel GJ, Rao SS. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 2012 Jun 6;30(26):3965-74.
              doi: 10.1016/j.vaccine.2012.03.026pubmed: 22449425google scholar: lookup
            9. Lewis NS, Daly JM, Russell CA, Horton DL, Skepner E, Bryant NA, Burke DF, Rash AS, Wood JL, Chambers TM, Fouchier RA, Mumford JA, Elton DM, Smith DJ. Antigenic and genetic evolution of equine influenza A (H3N8) virus from 1968 to 2007. J Virol 2011 Dec;85(23):12742-9.
              doi: 10.1128/JVI.05319-11pubmed: 21937642google scholar: lookup
            10. Gildea S, Arkins S, Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus. Influenza Other Respir Viruses 2010 Nov;4(6):363-72.
              doi: 10.1111/j.1750-2659.2010.00163.xpubmed: 20958930google scholar: lookup
            11. Cullinane A, Elton D, Mumford J. Equine influenza - surveillance and control. Influenza Other Respir Viruses 2010 Nov;4(6):339-44.
              doi: 10.1111/j.1750-2659.2010.00176.xpubmed: 20958927google scholar: lookup
            12. Bryant NA, Paillot R, Rash AS, Medcalf E, Montesso F, Ross J, Watson J, Jeggo M, Lewis NS, Newton JR, Elton DM. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak. Vet Res 2010 Mar-Apr;41(2):19.
              doi: 10.1051/vetres/2009067pubmed: 19863903google scholar: lookup
            13. Chambers TM, Quinlivan M, Sturgill T, Cullinane A, Horohov DW, Zamarin D, Arkins S, García-Sastre A, Palese P. Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Vet J 2009 Jan;41(1):87-92.
              doi: 10.2746/042516408x371937pubmed: 19301588google scholar: lookup
            14. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge. J Virol 2006 Aug;80(16):7929-38.
              doi: 10.1128/JVI.00263-06pubmed: 16873250google scholar: lookup
            15. Karaca K, Swayne DE, Grosenbaugh D, Bublot M, Robles A, Spackman E, Nordgren R. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 2005 Nov;12(11):1340-2.
              doi: 10.1128/CDLI.12.11.1340-1342.2005pubmed: 16275953google scholar: lookup
            16. Ma X, Zhang M, Zhang X, Qi T, Zhang W, Zhao Y, Na L, Zhang Y, Wang XF, Wang X. Construction and Immunogenicity Evaluation of a Recombinant Fowlpox Virus Expressing VP2 Gene of African Horse Sickness Virus Serotype 1. Microorganisms 2025 Dec 9;13(12).
              doi: 10.3390/microorganisms13122807pubmed: 41472010google scholar: lookup
            17. Atwa AS, Gomaa L, Elmenofy W, Amer HM, Ahmed BM. Expression of recombinant Florida clade 2 hemagglutinin in baculovirus expression system: A step for subunit vaccine development against H3N8 equine influenza virus. Open Vet J 2024 Jan;14(1):350-359.
              doi: 10.5455/OVJ.2024.v14.i1.32pubmed: 38633177google scholar: lookup
            18. Elliott S, Olufemi OT, Daly JM. Systematic Review of Equine Influenza A Virus Vaccine Studies and Meta-Analysis of Vaccine Efficacy. Viruses 2023 Nov 28;15(12).
              doi: 10.3390/v15122337pubmed: 38140577google scholar: lookup
            Subscribe to our newsletter
            Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.